Article
Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.
Journal of virology - 13 Apr 2022
Nuñez Castrejon Ana M, O'Rourke Sara M, Kauvar Lawrence M, DuBois Rebecca M
Abstract excerpt
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease of children, the elderly, and immunocompromised individuals. Currently, there are no FDA-approved RSV vaccines. The RSV G glycoprotein is used for viral attachment to host cells and impairment of host immunity by interacting with the human chemokine receptor CX3CR1. Antibodies that disrupt this interaction are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
